Browse Studies — Arctuva

Phase 2

A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Bronchiectasis With Pseudomonas Aeruginosa Colonization

Estimated

~$10 – $7,500

AstraZenecaNCT07088926

Phase 1

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung i…

Cystic Fibrosis LungRespiratory Infections, Recurrent, ChronicPseudomonas Aeruginosa

Estimated

~$10 – $8,750

Respirion Pharmaceuticals Pty LtdNCT06016088

Pathobiomes in Gut of Critically Ill Patients

Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in …

Pseudomonas Aeruginosa

Estimated

~$10 – $750

University of ChicagoNCT06822465

Phase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection

The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The…

Chronic Pseudomonas Aeruginosa InfectionCystic Fibrosis (CF)

Estimated

~$10 – $8,750

BiomX LtdNCT06998043